恒生生物科技指数大涨超2%。指数成份股中，亚盛医药B（06855）涨超8%；康诺亚-B（02162）涨 7%；信达生物涨5%。 钢铁股涨幅居前，上半年钢铁行业盈利大幅增长，机构称长期看产能治理仍是主线。马鞍山钢铁股份 (00323)超涨10%；鞍钢股份(00347)涨5%。 心动公司(02400)盈喜后大涨24%，预计上半年净利润同比增长约215%。 华虹半导体(01347)再涨超6%，北美客户PMIC需求高增带动业绩，新资产收购预计一年内完成。 正乾金融控股(01152)复牌飙升逾300%，午盘收涨224%。向债权人发行可换股债偿还债务。 和誉-B(02256)绩后涨5%，中期纯利同比增长58.8%至3.28亿，公司年内持续回购股份。 智通财经获悉，港股恒生指数涨0.27%，涨66点，报24799点；恒生科技指数涨0.33%。港股早盘成交 1124亿港元。 东方甄选(01797)涨超15%，近一个月股价实现翻倍，机构建议关注公司向产品驱动的转型。 中船防务(00317)再涨超6%，中国船舶吸收合并中国重工方案获批，公司未来有望参与整合。 蓝思科技(06613)涨超4%，超额配股权获悉数行使，昨日起正式进入港 ...

智通财经APP获悉，港股恒生指数涨0.27%，涨66点，报24799点；恒生科技指数涨0.33%。港股早盘成 交1124亿港元。 恒生生物科技指数大涨超2%。指数成份股中，亚盛医药B（06855）涨超8%；康诺亚-B（02162）涨 7%；信达生物涨5%。 钢铁股涨幅居前，上半年钢铁行业盈利大幅增长，机构称长期看产能治理仍是主线。马鞍山钢铁股份 (00323)超涨10%；鞍钢股份(00347)涨5%。 心动公司(02400)盈喜后大涨24%，预计上半年净利润同比增长约215%。 华虹半导体(01347)再涨超6%，北美客户PMIC需求高增带动业绩，新资产收购预计一年内完成。 正乾金融控股(01152)复牌飙升逾300%，午盘收涨224%。向债权人发行可换股债偿还债务。 东方甄选(01797)涨超15%，近一个月股价实现翻倍，机构建议关注公司向产品驱动的转型。 中船防务(00317)再涨超6%，中国船舶吸收合并中国重工方案获批，公司未来有望参与整合。 蓝思科技(06613)涨超4%，超额配股权获悉数行使，昨日起正式进入港股通名单。 东软睿新集团(09616)盈警后跌超15%，预计中期股东应占利润下降约20%-3 ...

Summary of Ascentage Pharma's Conference Call Company Overview - **Company**: Ascentage Pharma - **Key Products**: Lisatoclax (2,575) and Olverembatinib (Aurebatinib) Industry Insights - **Market Focus**: Hematological malignancies, specifically targeting CLL (Chronic Lymphocytic Leukemia), MDS (Myelodysplastic Syndromes), and MM (Multiple Myeloma) [2][6] - **Competitive Landscape**: The market for BCL-2 inhibitors is competitive, with Lisatoclax being the second BCL-2 inhibitor globally approved, following Venetoclax [19] Core Points and Arguments - **Lisatoclax Development**: - Submitted for CLL indication in China and plans to expand into MDS and MM, which have less competition [2][6] - Expected to leverage safety advantages to capture market share [2] - Clinical trial data presented at ASCO 2025 showed an ORR of 83.3% in AML patients and 43% in difficult-to-treat AML patients [23] - **Olverembatinib Performance**: - Achieved sales of 241 million RMB in 2024, with expectations to double in 2025 [3] - Positioned as a third-generation TKI targeting T315I resistant patients, showing significant safety advantages over competitors [11][15] - **Collaboration with Takeda**: - A $1.3 billion licensing agreement was reached, with Takeda expected to exercise options post-2026 [5] - This partnership indicates recognition of Chinese-developed drugs by international firms [5] - **Research and Development Focus**: - Future R&D investments will prioritize overseas registration and domestic indication expansions for Lisatoclax [4] - Cash flow is projected to support these initiatives [4] Additional Important Insights - **Market Potential**: - Lisatoclax's peak sales potential is estimated between $3 billion to $4 billion globally [19] - Olverembatinib's peak sales in overseas markets could reach $2 billion to $3 billion, with domestic sales expected to approach 2 billion RMB [18] - **Competitive Advantages**: - Lisatoclax offers better safety and faster dose escalation compared to Venetoclax, enhancing patient compliance [19] - The strategic approach of entering the market with a cautious clinical trial design allows for quicker market capture [22] - **Management and Shareholder Structure**: - Led by Dr. Yang Dajun, with a strong management team experienced in drug development [7] - Takeda is a significant shareholder, reflecting confidence in Ascentage's capabilities [8] - **Future Outlook**: - Plans to expand into ALL (Acute Lymphoblastic Leukemia) with Philadelphia chromosome-positive patients, which could significantly boost sales [14] - The company is also exploring new product pipelines targeting solid tumors and hematological malignancies [9] This summary encapsulates the key insights from Ascentage Pharma's conference call, highlighting the company's strategic direction, product performance, and market opportunities.

Group 1 - The core viewpoint of the news highlights the ongoing bullish trend in the innovative drug sector, driven by significant business development (BD) projects and active trading in related ETFs [1][2][3][4] - The Hong Kong stock market saw a slight increase in major indices, with a notable rise in biopharmaceutical stocks, indicating strong market interest in this sector [1] - Key innovative drug companies such as Hengrui Medicine, CSPC Pharmaceutical, and Lepu Biopharma have secured substantial overseas licensing agreements, which are expected to generate significant revenue [2][3] Group 2 - The innovative drug sector is anticipated to maintain momentum through 2025, supported by major academic conferences that will catalyze market interest [3] - There is a focus on emerging technologies and unmet clinical needs, with specific attention to areas such as dual-target and multi-target therapies, small nucleic acids, and next-generation immuno-oncology drugs [3] - The Hong Kong Innovative Drug Select ETF (520690) tracks a pure innovative drug index, which has shown impressive growth, making it a focal point for investors [4]

今年7月29日，和誉-B(02256)盘中最高股价达到11.74港元，创下公司近4年以来的股价新高，而这也让和誉年初至今的股价最大涨幅达到155.22%。 在高涨的股价让二级市场投资者投资回报水涨船高的同时，和誉也在持续通过注销式股票回购方式用"真金白银"回馈投资者。今年3月，和誉董事会再次批 准了公司动用2亿港元在市场上购回股份，截至今年6月30日，公司已累计回购954.50万股，合计7530万港元。 实际上，今年以来，港股创新药板块走出了一波大爆发行情。而从和誉最新披露的2025年中期财报投资者不难看出，随着创新研发与国际化BD预期的不断 兑现，公司顺利实现了持续性规模化的创新收益与盈利，并产生了丰富的现金流，为公司中长期创新研发提供了可观的资金保障，也进一步完善了公司"创 新-盈利"的正循环。今年上半年不断攀升的股价反映的便是市场对公司价值的高度认可。 规模化盈利预期获持续兑现 今年上半年，和誉得以实现规模化盈利预期的持续兑现，其中的关键载体便是商业化价值持续释放的核心品种匹米替尼。 作为首个中国自主研发进入全球III期TGCT临床试验的CSF-1R抑制剂，匹米替尼目前已获中美欧多国监管机构突破性疗法认 ...

Core Insights - Ascentage Pharma Group International is participating in the Evercore China Biotech Summit from August 19 to 21, 2025, in Shanghai, China [1][2] - The company is focused on addressing unmet medical needs in cancers and has developed a pipeline of innovative drug candidates [3] Company Overview - Ascentage Pharma is a global biopharmaceutical company with a rich pipeline targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [3] - The lead asset, olverembatinib, is the first third-generation BCR-ABL1 inhibitor approved in China for specific types of chronic myeloid leukemia (CML) and is included in the China National Reimbursement Drug List [4] - The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor recently approved for treating relapsed and/or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [5] Clinical Trials and Research - Ascentage Pharma is conducting several global registrational Phase III trials for olverembatinib and lisaftoclax, targeting various patient populations and conditions [4][5] - The company has established partnerships with leading biotechnology and pharmaceutical companies, enhancing its research and development capabilities [6]

Core Viewpoint - The innovative drug sector is experiencing a rebound after a period of adjustment, with significant gains in the Hang Seng Hong Kong Stock Connect Innovative Drug Index and notable performances from various companies [1] Group 1: Market Performance - As of 10:13, the Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 0.6% [1] - Notable stock performances include Lepu Biopharma-B up 4.5%, Ascentage Pharma-B up 4.0%, CSPC Pharmaceutical Group up 3.4%, Livzon Pharmaceutical Group up 3.1%, and CanSino Biologics up 2.7% [1] - The Hang Seng Innovative Drug ETF (159316) has seen net inflows for 13 consecutive trading days, reaching a record size of nearly 1 billion yuan [1] Group 2: Company Announcements - Haikang Pharmaceutical announced that its innovative drug HSK3486 (环泊酚注射液) has received FDA acceptance for its marketing application [1] - Huahai Pharmaceutical reported that its subsidiaries Huyao Tai and Huabo Biotech have received clinical trial approval from the National Medical Products Administration for the world's first dual-target antibody drug HB0043 targeting IL-17A and IL-36R [1] Group 3: Investment Opportunities - The achievements of innovative drug companies in China are noteworthy, indicating potential investment opportunities in the sector [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index reflects the performance of stocks related to innovative drug research, development, and production, focusing on leading companies in the Hong Kong innovative drug market [1] - The Hang Seng Innovative Drug ETF (159316) is the first ETF tracking this index, offering high elasticity and scarcity, allowing investors to benefit from the growth of the innovative drug industry [1]

Group 1 - Overseas business development continues to exceed expectations, with CSPC Pharmaceutical Group licensing its oral GLP-1 small molecule to Madrigal for a record upfront payment of $120 million, highlighting the premium capability of Chinese technology platforms [1] - Breakthrough in treatment paradigms with Shuyou Shen's C5a antibody BDB-001, which outperformed hormone therapy in treating anti-neutrophil cytoplasmic antibody vasculitis, achieving a complete response rate that is ten times higher, laying the foundation for subcutaneous formulations to enter international markets [1] - The National Healthcare Security Administration supports high-level innovative drugs, indicating satisfaction with pricing levels that correspond to high investment and risk, and is implementing measures to expedite the clinical launch of new drugs [1] Group 2 - Huazhong Securities emphasizes that innovative hard technology will remain a key focus in the pharmaceutical sector, including innovative drugs, devices, AI healthcare, and emerging technologies like brain-computer interfaces and robotics [2] - The Hong Kong Medical ETF closely tracks the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index, which selects 50 liquid and large-cap healthcare companies to reflect the overall performance of the sector [2] Group 3 - As of July 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index account for 62.91% of the index, including companies like Innovent Biologics, WuXi Biologics, and CSPC Pharmaceutical Group [3]

Group 1 - The core viewpoint is that the innovative drug valuation recovery trend is ongoing, driven by multiple catalysts such as international conferences, tariff exemptions, BD transactions, and better-than-expected semi-annual performance [1] - The Hang Seng Pharmaceutical ETF (159892) has seen a continuous rise for six months, with a remarkable increase of 23.8% in July, ranking high among all market ETFs [1] - On August 1, the Hong Kong pharmaceutical sector continued to rise against the trend, with the Hang Seng Pharmaceutical ETF (159892) surging over 2%, led by companies like Lepu Biopharma, Ascentage Pharma, CSPC Pharmaceutical Group, and CanSino Biologics [1] Group 2 - CSPC Pharmaceutical Group recently announced a significant BD order, which includes a prepayment of $120 million, potential development, regulatory, and commercial milestone payments up to $1.955 billion, and high double-digit sales royalties based on the annual net sales of SYH2086 [1]

港股创新药概念股盘初冲高，石药集团(01093.HK)涨超5%，亚盛医药(06855.HK)涨超4%，四环医药 (00460.HK)、丽珠医药(01513.HK)等跟涨。 ...